AstraZeneca has agreed to acquire U.S.-based vaccine developer Icosavax for $1.1 billion, the companies announced Tuesday, to gain access to experimental vaccines targeting common respiratory ...

By Rebecca Robbins AstraZeneca has started to pull its Covid-19 vaccine from global markets because of low demand, the pharmaceutical giant said. The decision closes the chapter on a shot that was ...

The pharmaceutical giant AstraZeneca on Tuesday said it is withdrawing its COVID-19 vaccine worldwide citing low demand and a "surplus of available updated vaccines" since the pandemic.

The company already had moved to pull the vaccine from European Union markets, and that became effective Tuesday. Related AstraZeneca to pay $425 million to settle Nexium, Prilosec lawsuits ...

A healthcare worker prepares doses of the AstraZeneca Covid-19 vaccine at a vaccine hub in the Auditorium della Tecnica in Rome in June 2021. AstraZeneca is withdrawing its highly successful ...

Languages: English and Urdu Pharmaceutical company AstraZeneca has initiated a global withdrawal of its COVID-19 vaccine just months after it admitted it could cause a rare side effect.

AstraZeneca is withdrawing its COVID-19 vaccine from worldwide circulation and marketing authorizations. The British-Swedish company recently acknowledged side effects such as blood clots and low ...